The Trump administration has made a deal with pharmaceutical companies Novo Nordisk and Eli Lilly to lower the costs of weight loss drugs. This affects FDA-approved GLP-1 treatments like Wegovy and Zepbound. A survey showed an increase in weight loss drug injections. The prices will be discounted under the TrumpRx platform, benefitting those without insurance coverage. Wegovy and Zepbound can be costly, but the deal aims to make them more accessible. Manufacturers offer self-pay programs for financial relief. The deal sets prices for Wegovy and Zepbound at $350 and $346 respectively through TrumpRx. Medicare prices are set at $245 for eligible patients. The deal aims to democratize pharmaceutical-assisted weight loss. Novo Nordisk and Eli Lilly may benefit from increased demand due to lower prices. Adjustments to earnings guidance and analyst opinions may be affected by the TrumpRx rollout. The deal may impact sales and margins for the companies. It’s unclear how the deal will affect demand and sales volume. Investors should monitor the companies’ guidance and analyst revisions post-TrumpRx rollout. The deal is still in the planning stage, so investment decisions should not solely rely on it. Novo Nordisk and Eli Lilly were not on the list of top 10 stocks to buy now. The Motley Fool Stock Advisor has a total average return of 1,035%. The deal could increase demand for weight loss products from budget-squeezed populations. Novo Nordisk and Eli Lilly’s involvement in TrumpRx is still in the planning stage.

Read more at Yahoo Finance: Eli Lilly and Novo Nordisk May Soon Sell Weight Loss Drugs on the Planned TrumpRx. Could This Further Boost the Healthcare Giants’ Stocks?